<DOC>
	<DOC>NCT01473251</DOC>
	<brief_summary>The purpose of this study is to measure biomarkers in the vitreous of patients undergoing Lucentis or avastin treatment.</brief_summary>
	<brief_title>Analysis of Growth Factors in Patients Undergoing Lucentis or Avastin Injections for Diabetic Macular Edema and Exudative Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Male or female age 18 to 85 with diabetes and hemoglobin A1C &lt;/= 10, or exudative macular degeneration. Diabetic macular edema with average retinal thickness central subfield &gt;/= 290um. Macular atrophy/fibrosis. Ocular antiVEGF treatment within 3 months. Treatment with topical or oral carbonicanhydrase inhibitor within one month Laser photocoagulation within 3 months (diabetic cohort)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>